Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Artialis | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Evaluation of efficacy and tolerance of a food supplement (MYOSTIM®) versus a placebo in postoperative revalidation of patients after reconstructive surgery of anterior cruciate ligament.
The food supplement (MYOSTIM®) has been developped and is supplied as food bars and composed of pomegranate, leucine, creatine, proteins and D vitamin. The aim of this exploratory study is to assess the efficacy and tolerance of MYOSTIM® on muscle performance after ACL reconstructive surgery and in postoperative revalidation phase.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MYOSTIM® | Active Comparator | MYOSTIM® 2 bars/day during 12 weeks MYOSTIM® as a food bar. Active ingredient: Pomegranate extract, L-leucine, Creatine, D3 Vitamin, Proteins IP Status: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment. |
|
| PLACEBO | Placebo Comparator | PLACEBO 2 bars/day during 12 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MYOSTIM® | Dietary Supplement | Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment. |
| Measure | Description | Time Frame |
|---|---|---|
| Assess the efficacy of MYOSTIM® on the muscular strength recovery | Evaluation by isokinetic test performed (extension/flexion of the quadriceps) | Change from Baseline at 14 weeks post ACL surgery |
| Assess the efficacy of MYOSTIM® on the muscular strength recovery | Evaluation by isokinetic test performed (extension/flexion of the hamstrings) | Change from Baseline at 14 weeks post ACL surgery |
| Assess the efficacy of MYOSTIM® on the muscular mass recovery | Evaluation by Magnetic Resonance Imaging (MRI) | Change from Baseline at 14 weeks post ACL surgery |
| Assess the efficacy of MYOSTIM® on the muscular mass recovery | Evaluation by impedancemetry | Change from Baseline at 14 weeks post ACL surgery |
| Assess the efficacy of MYOSTIM® on physical performance recovery | Evaluation with one self-administrated knee evaluation questionnaire from the International Knee Documentation Committee | Change from Baseline at 14 weeks post ACL surgery |
| Assess the effect of MYOSTIM® on blood biomarker | Evaluation of blood concentration of biomarker (Myostatin (muscular atrophy), Myeloperoxidase (chronic joint inflammation), Coll2-1 and Coll2-1NO2 (Cartilage inflammation and degradation), IL6 (muscular atrophy and inflammation), MMP3 and NT-CAF (cartilage and neuro-muscular junction), TNFa (inflammation)) | Change from Baseline at 2 and14 weeks post ACL surgery |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Related to the pathology:
Related to treatment:
Related to associated diseases:
Related to patient:
Related to MRI counter-indication:
Related to impedancemeter test:
• Patient with a metal plate at the right ankle
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Bois de l'Abbaye et de Hesbaye | Seraing | Liège | 4100 | Belgium | ||
| CHU de Liège |
Not provided
| ID | Term |
|---|---|
| D000070598 | Anterior Cruciate Ligament Injuries |
| ID | Term |
|---|---|
| D007718 | Knee Injuries |
| D007869 | Leg Injuries |
| D014947 | Wounds and Injuries |
Not provided
Not provided
Double blind, exploratory study, monocentric, with a group of control patient with placebo.
Two parallel-groups receiving during 12 weeks either the MYOSTIM® or a PLACEBO in a double blinded manner.
Not provided
Not provided
Two parallel-groups either the MYOSTIM® or a PLACEBO in a double blinded manner.
| PLACEBO | Dietary Supplement | Bars with no active ingredient and the same flavor (chocolate and red fruits). |
|
| Assess the efficacy of MYOSTIM® on the pain of the patient |
Evaluation of pain of the patient by one visual analogue scale (VAS) |
| Change from Baseline at 2 and14 weeks post ACL surgery |
| Assess the efficacy of MYOSTIM® on the global judgment of the patient | Evaluation of global judgment of the patient by one visual analogue scale (VAS) | Change from Baseline at 2 and14 weeks post ACL surgery |
| Assessment of the tolerance of the patient with the MYOSTIM® | Evaluation according the number of Adverse Events (AE), remaining bars and satisfaction scale for the product | At 14 weeks post ACL surgery |
| Assessment of the compliance of the patient with the MYOSTIM® | Evaluation according the number of remaining bars | At 14 weeks post ACL surgery |
| Assessment of the satisfaction of the patient with the MYOSTIM® | Evaluation according the satisfaction scale for the product | At 14 weeks post ACL surgery |
| Liège |
| 4000 |
| Belgium |